Sep 01,2020

ABBOTT'S FREESTYLE® LIBRE 2 ICGM SYSTEM NOW AVAILABLE TO MEDICARE BENEFICIARIES

Abbott announced today its next-generation FreeStyle® Libre 2 integrated continuous glucose monitoring (iCGM) system is now available to Medicare patients. Having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), the FreeStyle Libre 2 system is now accessible to all Medicare patients with diabetes who meet the eligibility criteria.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 16,2020

Almost Half Of People With Diabetes Need To Correct Insulin Doses

A survey conducted by Quin, a pioneering, female-founded, digital health start-up, finds that nearly half (46%) of people with type 1 diabetes need to correct their insulin doses under existing medical guidance.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 17,2020

ABBOTT INTRODUCES LIBRE SENSE GLUCOSE SPORT BIOSENSOR IN EUROPE, WORLD'S FIRST GLUCOSE BIOSENSOR DESIGNED FOR ATHLETES

Abbott is introducing the world's first glucose sport biosensor,i Libre Sense Glucose Sport Biosensor, which is designed for athletes to continuously measure glucose to better understand the correlation between their glucose levels and their athletic performance. The Libre Sense biosensor is based on Abbott's world-leadingii FreeStyle Libre continuous glucose monitoring technology, which was originally developed for people living with diabetes. Based on that technology, this is the first personal-use product that allows for use beyond diabetes.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 21,2020

Nemaura Medical Licenses Validated Mobile Application to Create Powerful Diabetes Prevention and Management Suite of Products

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has licensed the rights to Healthimation, LLC’s mobile application based digital program, a well-validated and award-winning 12-week program to help patients manage their weight and pre-diabetes or early diabetes conditions. The program is intended to be combined with the company’s proBEAT™ non-invasive patch CGM (continuous glucose monitor) for an enhanced behavioral change experience.

COLLABORATION PARTNERSHIP

#connected device

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 28,2020

ABBOTT'S FREESTYLE® LIBRE 3 SYSTEM RECEIVES CE MARK - FEATURES WORLD'S SMALLEST, THINNEST SENSOR WITH BEST-IN-CLASS PERFORMANCE AT THE SAME LOW COST FOR PEOPLE WITH DIABETES

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology,8 announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe. The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones2 every minute, offering unsurpassed 14-day accuracy1 in the smallest and thinnest3 sensor design at the same affordable price7 as previous versions of the device.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 30,2020

DreaMed Expands Its Remote Diabetes Solution to Four Clinics Across The U.S.

DreaMed Diabetes Ltd., the developer of the personalized, AI-based diabetes management solutions, announces its expansion across the U.S. through partnerships with a number of health clinics. The partnerships signal the active integration of DreaMed Advisor, a cloud-based remote insulin management technology into various clinics, including: Lucile Packard Children’s Hospital Stanford, the Billings Clinic in Montana, Hassenfeld Children’s Hospital at NYU Langone and UF Health.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 12,2020

Medtronic Launches InPen™ with Real-Time Guardian™ Connect CGM Data -- the First Integrated Smart Insulin Pen for People with Diabetes on MDI

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of InPen™ integrated with real-time1 Guardian Connect™ CGM data. InPen is the first and only FDA-cleared smart2 insulin pen on the market for people on multiple daily injections (MDI). This integrated system now provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes in one view.

PRODUCT

#connected device

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 23,2020

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Control-IQ™ technology. Control-IQ technology is an advanced hybrid closed-loop feature designed to help increase time in range (3.9-10 mmol/L)1 and deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.

REGULATORY FDA

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 02,2020

Abbott's Freestyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms

Abbott (NYSE:ABT) today announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval by Health Canada for adults and children (4 and older) with diabetes. With new features such as optional, real-time alarms that measure glucose levels every minute, FreeStyle Libre 2 gives users the option to be alerted in real-time of critical events such as hypoglycemia (low glucose levels) or hyperglycemia (high glucose levels).

PRODUCT

#cgm

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 17,2020

Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the official launch of its flagship program, BEAT®diabetes, and the availability of its proprietary non-invasive, daily-wear adhesive glucose monitor, proBEAT™.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM